# KPV (Anti-Inflammatory Tripeptide)

**Research Compilation Date:** December 4, 2025
**Evidence Level:** Preclinical Only (No Controlled Human Trials)
**Risk Profile:** UNCERTAIN (Long-term safety not established)

---

## What Is This?

KPV is a tiny three-amino-acid fragment (Lys-Pro-Val) from the end of α-MSH (the hormone that causes tanning). The clever part: it keeps the powerful anti-inflammatory effects but **doesn't cause tanning or sexual side effects** like full α-MSH or Melanotan. Animal studies show impressive results for IBD and wound healing — it inhibits NF-κB (a master inflammatory switch) and boosts the anti-inflammatory cytokine IL-10. However, **no controlled human trials exist**, so safety and efficacy remain unconfirmed.

---

## Categories

`Immune` · `Gut Health` · `Tissue Repair`

---

## Glossary

| Term | Meaning |
|------|---------|
| α-MSH | Alpha-Melanocyte Stimulating Hormone — causes tanning and has anti-inflammatory effects |
| NF-κB | Nuclear Factor kappa-B — a "master switch" that activates inflammation |
| IL-10 | Interleukin-10 — an anti-inflammatory cytokine (signalling molecule) |
| TNF-α, IL-1β, IL-6 | Pro-inflammatory cytokines that KPV suppresses |
| IBD | Inflammatory Bowel Disease (Crohn's, ulcerative colitis) |
| Enterocyte | Intestinal lining cells |
| Melanogenic | Causing skin darkening/tanning |

---

## Overview

KPV is a naturally occurring tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). It consists of the C-terminal amino acids Lysine-Proline-Valine and possesses potent anti-inflammatory and antimicrobial properties without the melanogenic (tanning) effects of the full α-MSH molecule. It has garnered significant interest for inflammatory bowel disease, wound healing, and systemic inflammation.

---

## Key Specifications

| Property | Value |
|----------|-------|
| Type | Tripeptide (α-MSH fragment) |
| Sequence | Lys-Pro-Val (KPV) |
| Molecular Weight | ~342 Da |
| Origin | C-terminal of α-MSH |
| Primary Effect | Anti-inflammatory |
| Key Advantage | No melanogenic/tanning effect |
| Administration | Oral, subcutaneous, topical |

---

## Mechanism of Action

KPV's anti-inflammatory power centres on four interlocking mechanisms. At the core is NF-κB inhibition — KPV blocks the activation of this master inflammatory switch, preventing the cascade that produces TNF-α, IL-1β, and IL-6. This isn't just suppression; it's strategic interception at a control point. Simultaneously, KPV enhances IL-10, the body's own anti-inflammatory cytokine, promoting a regulatory immune response that balances inflammation rather than simply crushing it. The result is tissue protection without immunosuppression.

Beyond immune modulation, KPV carries direct antimicrobial effects. It disrupts bacterial membranes, showing activity against multiple pathogens — particularly relevant for gut applications where microbial balance matters. In the intestinal lining itself, KPV promotes enterocyte integrity, supporting barrier function and aiding mucosal healing. This combination of anti-inflammatory, antimicrobial, and barrier-protective effects makes it especially compelling for inflammatory bowel disease.

The elegant part: KPV achieves all this without melanocortin receptor activation. While full α-MSH causes tanning, sexual effects, and appetite changes alongside its anti-inflammatory benefits, KPV retains only the therapeutic effects. It's the pharmaceutical equivalent of signal extraction — keeping what matters, discarding what doesn't.

| α-MSH Effect | KPV |
|--------------|-----|
| Anti-inflammatory | **Yes** |
| Tanning | **No** |
| Sexual effects | **No** |
| Appetite effects | **Minimal** |

---

## Clinical Evidence

The evidence picture for KPV is simultaneously promising and incomplete. Animal models of colitis show significant inflammation reduction, improved epithelial barrier integrity, and reduced clinical symptoms — exactly what you'd hope for in IBD treatment. The mechanisms are clean, the effects reproducible. Yet when you look for controlled human trials, you find none. Despite years of interest and compelling preclinical data, no randomized controlled trial has been published for KPV in humans for any indication. This creates a peculiar evidence gap: strong biological rationale and animal data, but zero formal human validation.

Wound healing studies paint a more complete picture. Chronic wounds show accelerated healing, burn wounds demonstrate reduced inflammation, and diabetic wounds exhibit improved closure rates. The antimicrobial data is straightforward: KPV inhibits S. aureus, E. coli, and C. albicans. Direct pathogen disruption combined with anti-inflammatory effects creates a dual mechanism for wound management.

The IBD application remains the most intriguing yet least validated. Animal colitis models are encouraging, but human inflammatory bowel disease is vastly more complex. The gap between rodent studies and human clinical validation represents the central uncertainty in KPV's profile — excellent theory and preclinical work, but the human trial data remains missing.

---

## Administration Routes

### Oral (For GI/Systemic)

| Parameter | Details |
|-----------|---------|
| Dose | 200-500mcg |
| Frequency | 1-2 times daily |
| Best for | IBD, gut inflammation |
| Absorption | May partially survive GI transit (small tripeptide) — extent of oral bioavailability not established in humans |

**Note on Oral Use:** While KPV's small size (3 amino acids) suggests it may survive GI degradation better than larger peptides, **human oral bioavailability has not been formally studied**. Claims about oral absorption are theoretical, not validated.

### Subcutaneous (Systemic)

| Parameter | Details |
|-----------|---------|
| Dose | 200-500mcg |
| Frequency | 1-2 times daily |
| Best for | Systemic inflammation |
| Bioavailability | Higher than oral |

### Topical (Wounds/Skin)

| Parameter | Details |
|-----------|---------|
| Concentration | Variable |
| Application | Directly to affected area |
| Best for | Wounds, skin inflammation |
| Formulation | Cream, solution |

---

## Dosing Protocols

### IBD/Gut Health

| Protocol | Dose | Duration |
|----------|------|----------|
| Conservative | 200mcg oral | Daily |
| Standard | 500mcg oral | Daily |
| Flare support | 500mcg 2x | During flares |

### Systemic Inflammation

| Protocol | Dose | Route |
|----------|------|-------|
| Low | 200mcg | SC daily |
| Standard | 500mcg | SC daily |

### Cycling

- Can be used continuously
- Some prefer cycles (30 days on, 30 off)
- No established optimal protocol

---

## Safety Profile

### Limited Safety Data

| Parameter | Assessment |
|-----------|------------|
| Toxicity | None reported in animal models |
| Adverse events | Minimal in preclinical studies |
| Long-term safety | **NOT ESTABLISHED** — no long-term human data |
| Drug interactions | None documented (but not systematically studied) |

**Important:** While KPV is a fragment of endogenous α-MSH, exogenous administration at pharmacological doses has **not been evaluated in controlled human trials**. Safety profile is theoretical, extrapolated from α-MSH data and animal studies.

### Advantages Over Full α-MSH/Melanotan

- No skin darkening
- No sexual side effects
- No nausea
- No blood pressure effects
- Simpler safety profile

### Side Effects (Rare)

| Effect | Frequency |
|--------|-----------|
| Injection site reaction | Occasional |
| Mild GI upset (oral) | Rare |
| Headache | Rare |

### Contraindications

- Known allergy
- Active infection (antimicrobial effect could affect microbiome)
- Pregnancy/breastfeeding (no data)

---

## Anecdotal Reports (User Experiences)

**Note:** These are unverified reports from online forums and should not be considered medical evidence.

| Use Case | User Reports |
|----------|--------------|
| IBD | *"IBD symptoms significantly reduced"*, *"Flares less frequent"*, *"Can tolerate more foods"* |
| Gut health | *"Gut healing improved"*, *"Blood markers improved"* |
| Wounds | *"Wounds healed faster"* |
| Inflammation | *"Joint inflammation better"*, *"No side effects noticed"* |

### Timeline Reported

| Timeframe | Observation |
|-----------|-------------|
| 1-2 weeks | Some symptom improvement |
| 4-8 weeks | More significant effects |
| Ongoing | Sustained benefits reported |

---

## Comparison with Anti-Inflammatory Options

| Option | Mechanism | Evidence | Side Effects |
|--------|-----------|----------|--------------|
| **KPV** | NF-κB, IL-10 | Preclinical+ | Minimal |
| BPC-157 | Multiple | Preclinical | Minimal |
| Corticosteroids | Multiple | Extensive | Significant |
| NSAIDs | COX inhibition | Extensive | GI, CV |
| Biologics (IBD) | Various | Extensive | Moderate |

**KPV Advantage:** Anti-inflammatory without immunosuppression or significant side effects.

---

## Applications

Interest in KPV clusters around five main areas, each with distinct evidence levels. IBD remains the flagship application — the combination of NF-κB inhibition, IL-10 enhancement, antimicrobial effects, and enterocyte protection creates a compelling gut-specific profile. Preclinical data is promising, though human validation remains pending. Chronic wounds represent a stronger application: the dual mechanism of accelerated healing plus antimicrobial coverage addresses both tissue repair and infection risk. Systemic inflammation sits in early territory, driven by the NF-κB inhibition mechanism but lacking specific clinical data. Autoimmune support remains theoretical, based on immune modulation effects but without condition-specific evidence. Skin conditions show early promise, leveraging the anti-inflammatory effects without systemic exposure concerns.

The synergy landscape is logical but largely unvalidated. Pairing KPV with BPC-157 combines inflammation control with multi-modal healing effects — complementary mechanisms targeting related pathways. Adding probiotics to KPV creates a gut health strategy that addresses both inflammatory tone and microbial balance. Combining KPV with low-dose naltrexone for IBD support stacks two distinct immune modulators, though this remains entirely empirical territory without clinical trials of either agent for IBD, let alone the combination.

---

## Quality and Storage

### Quality Indicators

- White powder
- High purity (>98%)
- Third-party testing
- Proper certificate of analysis

### Storage

| Form | Storage |
|------|---------|
| Lyophilized | Refrigerated or frozen |
| Reconstituted | Refrigerate, use within weeks |
| Capsules | Room temperature |

---

## Practical Recommendations

### For IBD/Gut Health

1. **Consult GI specialist first**
2. **Start conservative:** 200mcg oral
3. **Increase gradually:** To 500mcg
4. **Track symptoms:** Keep symptom diary
5. **Continue standard therapy:** KPV is adjunctive

### For Wounds/Skin

1. **Clean wound first**
2. **Apply topical KPV**
3. **Cover appropriately**
4. **Monitor healing**
5. **Seek medical care for serious wounds**

### Who Might Benefit

- IBD patients (adjunctive)
- Chronic inflammation
- Wound healing issues
- Those avoiding steroids
- Systemic inflammation

---

## The α-MSH Connection

### Understanding the Origin

α-MSH (13 amino acids) has multiple effects:
- Tanning (melanogenesis)
- Anti-inflammatory
- Sexual effects
- Appetite effects

KPV (last 3 amino acids) retains:
- Anti-inflammatory
- Antimicrobial

**Result:** Therapeutic benefits without unwanted melanocortin effects.

---

## References

1. Brzoska T, et al. (2008) "Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects." Endocr Rev.

2. Kannengiesser K, et al. (2008) "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Inflamm Bowel Dis.

3. Getting SJ, et al. (2003) "Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis." Arthritis Rheum.

4. Capsoni F, et al. (2007) "Melanocortin peptides and their receptors in rheumatic diseases." J Leukoc Biol.

5. Luger TA, et al. (2003) "α-Melanocyte-stimulating hormone as a mediator of tolerance induction." Pathobiology.

---

*KPV is a promising anti-inflammatory tripeptide derived from α-MSH with growing interest for IBD, wound healing, and systemic inflammation. Its excellent safety profile and lack of melanogenic effects make it attractive compared to the full α-MSH molecule. Evidence is primarily preclinical with early clinical data emerging.*
